Literature DB >> 16461321

Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.

Alexander Claviez, Cornelia Eckert, Karl Seeger, André Schrauder, Martin Schrappe, Günter Henze, Arend von Stackelberg.   

Abstract

We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16461321

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

Review 2.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

3.  XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.

Authors:  S Rafiq; C Cheney; X Mo; D Jarjoura; N Muthusamy; J C Byrd
Journal:  Leukemia       Date:  2012-02-15       Impact factor: 11.528

4.  Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia.

Authors:  Veronika Bachanova; Karamjeet Sandhu; Sophia Yohe; Qing Cao; Michael J Burke; Michael R Verneris; Daniel Weisdorf
Journal:  Blood       Date:  2011-03-14       Impact factor: 22.113

Review 5.  Isolated extramedullary relapse in childhood acute lymphocytic leukemia.

Authors:  James E Jacobs; Caroline Hastings
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 3.952

6.  Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Jeevan Kumar; Afaq Ahmad Khan; Amrita Saraf; Manorama Bhargava
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-06       Impact factor: 0.900

7.  Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Authors:  Sébastien Maury; Françoise Huguet; Thibaut Leguay; Francis Lacombe; Marc Maynadié; Sandrine Girard; Adrienne de Labarthe; Emilienne Kuhlein; Emmanuel Raffoux; Xavier Thomas; Patrice Chevallier; Agnès Buzyn; André Delannoy; Yves Chalandon; Jean-Paul Vernant; Philippe Rousselot; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Marie-Christine Béné
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

8.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Authors:  Michael N Dworzak; Angela Schumich; Dieter Printz; Ulrike Pötschger; Zvenyslava Husak; Andishe Attarbaschi; Giuseppe Basso; Giuseppe Gaipa; Richard Ratei; Georg Mann; Helmut Gadner
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

Review 9.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.